Online inquiry

IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4264MR)

This product GTTS-WQ4264MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets LINGO1 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001301186.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84894
UniProt ID Q96FE5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4264MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4713MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ3492MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ10956MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ11648MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ10817MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ8327MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ11870MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ11315MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-524
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW